Cleo Diagnostics Ovarian Cancer Blood Test Case Study

This case study details the development of a blood test by Cleo Diagnostics aimed at providing early diagnosis for ovarian cancer, a significant health concern for women. The document outlines the challenges associated with diagnosing ovarian cancer, which often goes undetected until advanced stages due to a lack of symptoms and adequate screening methods. Cleo's blood test, which measures biomarkers in blood samples, is positioned to improve clinical workflows and enhance patient outcomes. The study also highlights the collaboration between Cleo and Clarivate, emphasizing the role of Clarivate's market research, regulatory insights, and intellectual property strategies in supporting Cleo's efforts to bring the test to market. The case study presents the potential impact of this diagnostic tool on women's health, aiming for broader screening programs and improved survival rates through early detection.